PGNX News and Press, Progenics Pharmaceuticals Inc. From 08/05/19

Top-line Data Now Expected by Year End Reaches Alignment with FDA on Regulatory Path; Company to Submit NDA Following Positive CONDOR Data Completed Enrollment in Pivotal Phase 3 Trial in Eight Months NEW YORK, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (N...

NEW YORK, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that it will host a conference call and webcast to review seco...

Cellectar Biosciences (NASDAQ: CLRB ) initiated with Buy rating and $6 (180% upside) price target at Brookline Capital. Shares up  8%  premarket. More news on: Cellectar Biosciences, Inc., Heat Biologics, Inc., Progenics Pharmaceuticals, Inc., Healthcare stocks news, Stocks on th...

Progenics Pharmaceuticals ( PGNX -2.1% ) will collaborate with the VA Greater Los Angeles Healthcare System on the company's AI research program related to medical imaging modalities. More news on: Progenics Pharmaceuticals, Inc., Healthcare stocks news, Read more ...

NEW YORK and WASHINGTON, July 25, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging technology for targeting and treating cancer, announced their collaboration with the VA Greater Los Angeles Healthcare Sy...

ALPHARETTA, Ga. , July 22, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with the other members of its group, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company")(NASDAQ: PGNX), comprised of successful specialty pharmaceu...

Court Upholds The Validity And Determined Actavis' Infringement Of Patent Protecting RELISTOR® Tablets Canada NewsWire BRIDGEWATER, N.J. and NEW YORK, July 17, 2019 BRIDGEWATER, N.J. and NEW YORK , July 17, 2019 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX:...

NEW YORK, July 12, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that, based on the preliminary voting results of its 2019 Ann...

NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, encourages all shareholders to vote today “ FOR ” all of the Bo...

ALPHARETTA, Ga. , July 8, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with the other participants in its solicitation, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company")(NASDAQ:PGNX), comprised of successful specialty...